Abbreviations: FSH, follicle-stimulating hormone; IVF, in vitro fertilization; IVG, in vitro growth; IVM, in vitro maturation; mTORC1, mammalian target of rapamycin complex 1; PTEN, phosphatase and tensin homolog deleted on chromosome ten.
| INTRODUC TI ON
The ability to develop human immature oocytes in vitro would have many potential applications but would be of particular relevance to fertility preservation. Ovarian tissue cryopreservation is now an option for women with cancer prior to undergoing gonadotoxic treatments. 1 Re-implantation of cryo-preserved tissue is currently the only option to use stored tissue, but in many cases, particularly for women with leukemia, malignant cells are present in the ovary and therefore re-implantation is not an option; however, the oocytes within this tissue could potentially be grown in vitro. 1 Culture systems with the aim of achieving in vitro growth (IVG) of immature oocytes to maturity and subsequent fertilization in vitro (IVF) have been the subject of research for almost 40 years. Several systems that support the growth of later stages of follicle development from rodents have been developed [2] [3] [4] [5] [6] [7] [8] with some reporting the production of live young. 3, 4, [6] [7] [8] Complete development from the most immature oocytes (primordial stages) in vitro with subsequent IVF of oocytes followed by embryo transfer and production of offspring has been achieved in the mouse using a two-step culture system. 9, 10 The initial studies resulted in the birth of one mouse which developed abnormalities as an adult. 9 Following alterations to the culture medium, several mouse embryos and offspring have been obtained using IVG oocytes then combined with in vitro maturation (IVM) and IVF. 10 More recently, in vitro systems that support complete development of murine oocytes starting from induced pluripotent stem cells 11 and from primordial germ cells 12 have been reported and these systems have resulted in competent oocytes that produce embryos and live young.
The work on rodents has provided proof of principle and has encouraged the challenge of adapting these systems to support human oocyte development in vitro. IVG of primordial follicles would be of particular benefit to pre-pubertal girls undergoing fertility preservation before being exposed to damaging chemotherapy. 13 Currently, the only fertility preservation option for prepubertal girls is storage tion, the ultimate aim is to achieve complete oocyte development from this tissue in vitro. The ability to develop human oocytes from the earliest follicular stages through to maturation and fertilization in vitro would revolutionize fertility preservation practice. This has been achieved in mice where in vitro grown oocytes from primordial follicles have resulted in the production of live offspring. Systems that support growth and development of oocytes from human ovarian cortex are being developed by several groups. This review focuses on the steps required to recapitulate in vitro the process of human oocyte development from the primordial stage and the systems currently available to support this.
K E Y W O R D S
follicle culture, in vitro activation, in vitro growth, in vitro maturation, oocyte, primordial follicles of ovarian cortical tissue with the potential for reimplantation at a later time. 13 In cases where reimplantation is not possible, IVG could provide another option to restore fertility. For IVG to be clinically viable, the process would need to start with primordial follicles since cortical strips that are stored contain predominantly this stage.
Although there still remains much detailed research to be carried out before IVG of primordial follicles could ever be clinically applied, a great deal of progress has been made in developing culture techniques to support human oocyte development in vitro. In this review, the current status of human IVG from primordial follicles will be considered.
| S TAG E S OF FOLLI CLE DE VELOPMENT
The majority of follicles within the ovary in all young mammalian females will be at the primordial stage of development and these follicles are continually utilized throughout reproductive life. 14 
It
is not known whether the pool of primordial follicles represents a homogeneous population, but at this stage follicles have not yet been exposed to selection processes that lead to follicle degeneration. 15 17, 18 The oocyte is held in meiotic arrest as it grows within the follicle and it must acquire the ability to resume meiosis (meiotic competence) as well as the ability to support fertilization and embryonic development (developmental competence). Oocyte development is dependent upon the environment of the individual follicle for its function as a gamete and this is regulated by inhibitory and stimulatory endocrine, paracrine, and autocrine signaling by the somatic cells of the follicle (granulosa and surrounding theca cells) enhanced by several oocyte-specific factors mediated through bi-directional communication. 19, 20 The physiological requirements of the oocyte, granulosa, and theca cells are extremely complex and dynamic, therefore recapitulating the process of follicle activation and growth in vitro is one of the greatest technical challenges in reproductive technology. 18 
| G ROWING H UMAN FOLLI CLE S IN VITRO
Several approaches have been taken to support early human follicle development in vitro starting with primordial follicle activation. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Although there are several culture systems that support a specific stage of human oocyte development in vitro, there is so far only one report that supports human primordial follicles to the stage of meiotic maturation. 30 To achieve complete development of human oocytes in vitro, a multi-step culture system is required. 26, 30, 32 The first step in this process is to facilitate the initiation of primordial follicle development and support early growth; the second step is to optimize the growth of follicles from preantral to antral stages; the third step supports the completion of oocyte growth ready for IVM in the fourth step ( Figure 1 ). In optimizing a culture system to obtain developmentally competent oocytes, the focus should be on oocyte development, which may preclude the need to develop large follicular structures in vitro. The multi-step approach needs to support the changing requirements of the developing oocyte and its surrounding somatic (granulosa) cells, while maintaining good oocyte-somatic cell interactions. Therefore, providing conditions that support the maintenance of appropriately differentiated somatic cells in contact with the developing oocyte similar to the oocyte granulosa cell complexes in the rodent system is essential. 4,10
| IVA : IN VITRO AC TIVATI ON OF HUMAN PRIMORDIAL FOLLICLE S
The majority of follicles within ovarian cortical tissue will be at the quiescent primordial stage. Activation of primordial follicles in vitro (IVA) and early follicle development are key features of any IVG system. Human primordial follicles can be activated and grow well within mechanically loosened cortical pieces, developing to multilaminar preantral (secondary) stages within 6 days. 26, 30 Central to this process is preparation of the ovarian tissue. This involves removal of most of the underlying stromal tissue and any growing follicles so that the cultured tissue consists of ovarian cortex containing primordial and primary follicles. When these small fragments of human ovarian cortex are cultured there is a significant shift of follicles from the quiescent to the growing pool over short periods of 6-10 days. 26, [29] [30] [31] It remains unclear how follicle activation is controlled but it is known to involve a combination of inhibitory, stimulatory and maintenance factors. 33 The importance of the phosphatidylinositol-3′-kinase (PI3K-AKT) signaling pathway within the oocyte has been implicated in regulating activation of primordial follicles using mouse knockout models 34 and in human using culture of ovarian cortex. 29, 35, 36 The phosphatase and tensin homolog deleted on
Key message
In vitro growth of immature oocytes from cryo-preserved ovarian cortex has the potential to produce mature oocytes but is still at an experimental stage. Further research is required before clinical application can be realized. | 655 chromosome ten (PTEN) acts as a negative regulator of this pathway and suppresses initiation of follicle development. 34 The transcription factor Forkhead Protein O3 (FOXO3) is a downstream effector of this pathway and acts to inhibit follicle recruitment. 37 Other components of this pathway are dependent on the mammalian target of rapamycin complex 1 (mTORC1), a serine/threonine kinase that regulates cell growth and proliferation in response to growth factors and nutrients, and also regulates primordial follicle activation. 38 From knockout mouse data it appears that whereas PTEN within the oocyte suppresses activation of primordial follicles, mTORC promotes it. How these pathways regulate human follicle development is unclear but culture models facilitate the study of these processes. 29, 36, 39 Significant primordial follicle activation occurs in step one of the multi-step culture system. 26, 30 This activation appears to be as a result of disrupting the Hippo signaling pathway during the preparation of the tissue. 36, 40, 41 Hippo disruption increases expression of downstream growth factors but manipulation of the PI3K pathway results in further activation. 29, 35, 36, 40, 41 Inhibition of PTEN in cultured human ovarian cortex results in increased activation of primordial follicles and more secondary follicles, but subsequent growth and survival of isolated secondary follicles is compromised. 29, 36 The detrimental effect on secondary follicles may be as a result of alterations in DNA damage and repair responses, as demonstrated recently in a bovine culture model. 42 Cortical strip culture removes follicles from the in vivo endocrine and paracrine processes regulating growth rate; however, follicles will still be subject to the effect of follicle interactions and the influence of stromal cell factors. It is clear that tissue shape and stromal density are important factors that contribute to the regulation of follicle growth initiation in vitro, as solid cubes of cortical tissue show lesser growth initiation 21 than cortex cultured as flattened 'sheets', where much of the underlying stroma is removed. 26, 30 The physical environment of the follicles within the cortical tissue affects their response to stimulatory and inhibitory factors and therefore influences their ability to grow. 43 Once follicle growth has been initiated within cortical tissue, they can develop to multi-laminar stages but do not survive well within the cortical environment, as growth is inhibited, resulting in loss of follicle integrity and oocyte survival. 22, 26 Growing follicles need to be released from the cortical stromal environment and cultured individually to limit the effect of follicle interactions. 26, 30, 31, 44 
| IVG : IN VITRO G ROW TH OF H UMAN PRE ANTR AL FOLLI CLE S
Preantral follicles can be isolated from cortical tissue post culture by mechanical dissection, enzymatic isolation or a combination of both. Collagenase and DNase can be used to remove preantral follicles from stromal tissue; however, collagenase can cause damage which leads to poor survival of follicles. 45 The presence of theca layers is required for growing follicles to retain their structure and survive the second stage of IVG and these may be compromised by collagenase. 45 More purified enzyme preparations such as Liberase™ may avoid the damage that occurs with collagenase. 46, 47 Mechanical isolation of follicles has the advantage of preserving follicular integrity by maintaining the basal lamina and thecal layers; however, the procedure is laborious and results in a low yield. 26, 30 Supporting the growth of human preantral follicles in vitro has led to the development of matrices to maintain follicle structure.
Alginate hydrogels has been used to encapsulate human preantral follicles and support their growth in vitro. 48 Alginate encapsulation is thought to mimic the extracellular matrix in vivo in terms of its ability to facilitate molecular exchange between the follicle and the culture medium. Its flexibility can accommodate cell proliferation but its rigidity prevents dissociation of the follicular unit. The rigidity of the alginate capsule affects follicle development, as inhibition of growth and reduced steroidogenesis have been reported in murine follicles embedded in 1% alginate gels, 49 whereas fully grown human oocytes have been produced using 0.5% gels. 48 The application of tissue engineering to support the growth of isolated follicles has been making progress; decellularized ovarian tissue and 3D microporous scaffolds are being explored as matrices to support preantral follicle growth. 50, 51 Recent work has explored the production of electrospun patterned porous scaffolds which may be more accessible and reproducible than decellularized tissue. 52 Engineered scaffolds clearly have great potential and should be developed further to support human follicle growth in vitro.
The multi-step culture system that has been developed for human follicles 30 does not use matrices or scaffolds to support the growth of isolated preantral follicles. Isolated growing follicles are cultured in v-shaped micro-well plates and this has supported follicular architecture in vitro while promoting growth, differentiation and antral formation. 26, 30 Once follicles are isolated from the ovarian cortex, their progression in vitro is remarkable. Secondary human follicles isolated enzymatically from fresh ovarian tissue and cultured in the presence of follicle-stimulating hormone (FSH) become steroidogenically active and complete oocyte growth within 30 days, 48 and these oocytes have been shown to be capable of meiotic maturation. 53 Primordial follicles grown within fragments of ovarian cortex to multi-laminar stages which are then isolated without the use of enzymes and cultured in the presence of activin and FSH become steroidogenic within 10 days of IVG. 26, 30 During step 2 of the multi-step system, isolated follicles cultured individually form antral cavities within 6-8 days. At this stage oocyte-granulosa cell complexes can be retrieved by applying gentle pressure to the follicle. Complexes with complete cumulus and adherent mural granulosa cells are selected for step 3 of the multi-step system (Figure 1 ). 30 Step 3 involves culturing the complexes on membranes in the presence of activin-A and rhFSH for up to 4 days until oocytes reach a diameter of 100 μm. 30 That in vitro grown follicles can produce fully grown oocytes after a relatively short culture period confirms that local ovarian factors inhibit follicle development in vivo. Oocyte size is an indicator of its ability to resume meiosis and therefore sustaining oocyte growth is the major objective of any complete in vitro development system. 17 There are clearly differences in growth rate depending on whether the whole follicle is cultured 48, 53 or complexes are removed for further growth after an antral cavity has formed. 26, 30 Whether the growth rate observed in vitro should be characterized as accelerated is not clear. The rate observed represents uninhibited growth without brakes that are required in vivo to regulate follicle development within the context of the reproductive cycle. Comparisons of culture systems are needed to determine optimal conditions but at this time there is only one complete system that supports growth from human primordial to maturation. 30 The next step is to determine whether the growth pattern in vitro can support the development of healthy oocytes or whether it is deleterious to oocyte function, epigenetic changes and health.
| MEI OTI C MATUR ATI ON OF OO C Y TE S FROM IVG H UMAN FOLLICLE S
The final stage in the IVG process before IVF can take place, is IVM to support resumption of meiosis to the point of Metaphase II ( Figure 1 ). IVM has been a successful strategy for embryo production in domestic species and has been applied to human oocytes with varying degrees of success. 54, 55 The first live birth after IVM of immature oocytes was reported in 1991, 56 although IVM was being utilized during the early development of IVF. 57 IVM is performed in a limited number of centers and success rates vary with the main factor being oocyte source and stage. 55 The rate of maturation of immature oocytes remains below that of oocytes harvested from stimulated ovaries, indicating that the protocols are sub-optimal or that many of the harvested oocytes are intrinsically unable to undergo maturation. 54, 55 The IVG oocytes derived from the multi-step culture system undergo meiotic maturation following an IVM protocol. 30 These oocytes form Metaphase II spindles but emit abnormally large polar bodies. 30 Polar body size is influenced by the proximity of the spindle to the oocyte cortex and the inter-chromosomal spacing within Metaphase II spindles. 58 If there is a loss of spindle contact with the oocyte cortex, this can lead to extrusion of large polar bodies. 59 The cause of the large polar bodies in the IVG-derived oocytes is not known but it indicates that culture conditions need to be further optimized. The consequences of such abnormalities on chromosome balance in mature oocytes need to be investigated.
While acknowledging that there are no fully optimized culture systems for human oocytes, there is now proof of concept that complete IVG of human oocytes is possible. 30 The end point of any IVG system is to produce developmentally competent and epigenetically normal oocytes; therefore future research needs to focus on optimizing each of the stages and gaining further understanding of the epigenetic status of IVG oocytes and of any embryos formed. 60 
| SUMMARY
The most significant clinical application of IVG of human oocytes is in fertility preservation given the widespread adoption of ovarian tissue cryopreservation for cancer patients. 1 It is clear that making a good egg is not an easy or straightforward process. 18 If reliable methodology could produce in vitro generated mature human oocytes capable of fertilization, this would be a viable alternative to autologous transplantation. Apart from the clinical implications and potential of the various IVG systems, each of them provide access to the process of human oogenesis in an experimentally tractable paradigm. Through these systems we will gain greater understanding of human oocyte development, ultimately leading to improvements in fertility preservation.
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None to declare. F I G U R E 1 Diagrammatic representation of a multi-step culture system to support in vitro growth (IVG) of oocytes from human primordial follicles through to maturation as described by McLaughlin et al. 30 Step 1, in vitro activation within micro-cortex for 7 d (a), then micro-dissection of multi-laminar growing follicles to be placed in step 2 (b) and cultured individually until antral formation occurs (c).
Step 3, isolation of the oocyte granulosa complex (d) from the intact follicle for further growth on membranes for up to 4 d (e).
Step 4, oocytecumulus complexes placed within medium for in vitro maturation (IVM). Oocytes are then analyzed for the presence of a Metaphase II spindle and a polar body. Fertilization of IVG human oocytes has not yet been tested. [Colour figure can be viewed at wileyonlinelibrary.com]
